Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | GIPR | P48546 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031874 | 1.00 | CCR2 (0.46) | CCR2EPHX2CCR3TMPRSS4CCR5 | |
| SCHEMBL5029656 | 0.79 | CCR2 (0.57) | CCR2EPHX2CCR5CYP2D6KCNH2 | |
| SCHEMBL5029650 | 0.79 | CCR2 (0.57) | CCR2EPHX2CCR5CYP2D6KCNH2 | |
| SCHEMBL5031879 | 0.79 | CCR2 (0.57) | CCR2EPHX2CCR5CYP2D6KCNH2 | |
| SCHEMBL5031877 | 0.79 | CCR2 (0.57) | CCR2EPHX2CCR5CYP2D6KCNH2 | |
| SCHEMBL5029307 | 0.77 | CCR2 (0.52) | CCR2EPHX2TMPRSS4POLBKMT2A | |
| SCHEMBL5029300 | 0.77 | CCR2 (0.52) | CCR2EPHX2TMPRSS4POLBKMT2A | |
| SCHEMBL3425203 | 0.77 | CCR2 (0.63) | CCR2CYP2D6KCNH2 | |
| SCHEMBL3425201 | 0.77 | CCR2 (0.63) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5142357 | 0.75 | POLB (0.57) | CCR2EPHX2TMPRSS4POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCR2 3/4885EPHX2 2676/4885CCR3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.